Predictive Oncology set to market its flagship artificial intelligence drug discovery platform

Predictive Oncology Inc (NASDAQ: POAI) is set to be a first mover in the artificial intelligence (AI) powered drug discovery market that the company estimates will grow to $20 billion in the next three years. The Minneapolis, Minnesota-based company outlined its strategy for 2022 and revealed that it plans to leverage its existing pharma relationships to market PeDAL in a move that will take the proprietary platform out of the research lab into the pipelines of oncology drug discovery companies. Predictive Oncology recently completed its Discovery 21 evaluation, which is the proof-of-concept for PeDAL. CoRE, the company's AI program, together with tumor profile data, human tumor samples and active machine learning, power PeDAL to determine the most effective drug treatment for a specific cancer type. Investors responded well, sending shares of Predictive Oncology nearly 5% higher to $0.84 in the pre-market trading session.